Free Trial

Organon & Co. (OGN) Financials

Organon & Co. logo
$13.90 -0.01 (-0.04%)
As of 11:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Organon & Co.

Annual Income Statements for Organon & Co.

This table shows Organon & Co.'s income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
3,218 2,160 1,351 917 1,023 864 187
Consolidated Net Income / (Loss)
3,218 2,160 1,351 917 1,023 864 187
Net Income / (Loss) Continuing Operations
3,306 2,256 1,351 917 1,023 864 187
Total Pre-Tax Income
3,696 2,752 1,529 1,122 673 807 425
Total Operating Income
3,762 2,787 1,791 1,570 1,257 1,374 824
Total Gross Profit
5,503 4,413 3,905 3,880 3,748 3,715 3,313
Total Revenue
7,777 6,532 6,304 6,174 6,263 6,403 6,216
Operating Revenue
7,777 6,532 6,304 6,174 6,263 6,403 6,216
Total Cost of Revenue
2,274 2,119 2,399 2,294 2,515 2,688 2,903
Operating Cost of Revenue
2,274 2,119 2,399 2,294 2,515 2,688 2,903
Total Operating Expenses
1,741 1,626 2,114 2,310 2,491 2,341 2,489
Selling, General & Admin Expense
1,443 1,356 1,668 1,704 1,893 1,760 1,721
Research & Development Expense
220 210 443 578 536 550 372
Impairment Charge
- - - - 0.00 0.00 301
Restructuring Charge
78 60 3.00 28 62 31 95
Total Other Income / (Expense), net
-66 -35 -262 -448 -584 -567 -399
Interest Expense
- 0.00 258 422 527 520 504
Other Income / (Expense), net
-66 -35 -4.00 -26 -57 -47 105
Income Tax Expense
390 496 178 205 -350 -57 238
Basic Earnings per Share
$12.69 $8.52 $5.33 $3.61 $4.01 $3.36 $0.72
Weighted Average Basic Shares Outstanding
253.52M 253.52M 253.54M 254.08M 255.24M 257.05M 259.50M
Diluted Earnings per Share
$12.69 $8.52 $5.31 $3.59 $3.99 $3.33 $0.72
Weighted Average Diluted Shares Outstanding
253.52M 253.52M 254.19M 255.17M 256.27M 259.15M 260.76M
Weighted Average Basic & Diluted Shares Outstanding
- - 253.64M 254.38M 255.64M 257.95M 260.32M
Cash Dividends to Common per Share
- - $0.56 $1.12 $1.12 $1.12 $0.34

Quarterly Income Statements for Organon & Co.

This table shows Organon & Co.'s income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
201 195 359 109 87 145 160 -205 146 108 164
Consolidated Net Income / (Loss)
201 195 359 109 87 145 160 -205 146 108 164
Net Income / (Loss) Continuing Operations
201 195 359 109 87 145 160 -205 146 108 164
Total Pre-Tax Income
236 235 207 129 101 229 243 -148 213 183 255
Total Operating Income
376 371 339 288 233 324 358 -91 235 322 365
Total Gross Profit
957 939 923 896 841 874 857 741 783 847 869
Total Revenue
1,622 1,607 1,582 1,592 1,513 1,594 1,602 1,507 1,460 1,558 1,574
Operating Revenue
1,622 1,607 1,582 - 1,513 1,594 1,602 1,507 1,460 1,558 1,574
Total Cost of Revenue
665 668 659 696 672 720 745 766 677 711 705
Operating Cost of Revenue
665 668 659 696 672 720 745 766 677 711 705
Total Operating Expenses
581 568 584 608 608 550 499 832 548 525 504
Selling, General & Admin Expense
431 437 422 470 420 453 415 433 424 434 421
Research & Development Expense
127 131 162 130 102 95 84 91 93 91 83
Restructuring Charge
23 0.00 0.00 8.00 86 2.00 0.00 7.00 31 0.00 0.00
Total Other Income / (Expense), net
-140 -136 -132 -159 -132 -95 -115 -57 -22 -139 -110
Interest Expense
131 131 126 153 124 131 128 109 111 108 106
Other Income / (Expense), net
-9.00 -5.00 -6.00 -6.00 -8.00 36 13 52 89 -31 -4.00
Income Tax Expense
35 40 -152 20 14 84 83 57 67 75 91
Basic Earnings per Share
$0.78 $0.76 $1.39 $0.43 $0.34 $0.56 $0.61 ($0.79) $0.56 $0.41 $0.62
Weighted Average Basic Shares Outstanding
255.70M 257.29M 257.50M 257.05M 257.86M 259.94M 259.98M 259.50M 260.37M 262.61M 262.62M
Diluted Earnings per Share
$0.78 $0.75 $1.38 $0.42 $0.33 $0.56 $0.61 ($0.78) $0.55 $0.40 $0.60
Weighted Average Diluted Shares Outstanding
258.36M 258.60M 259.76M 259.15M 261.00M 260.16M 260.65M 260.76M 262.90M 270.45M 272.38M
Weighted Average Basic & Diluted Shares Outstanding
257.17M 257.47M 257.54M 257.95M 259.96M 259.97M 259.98M 260.32M 262.60M 262.61M 262.62M

Annual Cash Flow Statements for Organon & Co.

This table details how cash moves in and out of Organon & Co.'s business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
75 -246 667 -31 -13 -18 -101
Net Cash From Operating Activities
3,020 2,284 2,160 858 799 939 700
Net Cash From Continuing Operating Activities
3,020 2,284 2,160 858 799 939 700
Net Income / (Loss) Continuing Operations
3,306 2,256 1,351 917 1,023 864 187
Consolidated Net Income / (Loss)
- - 1,351 917 1,023 864 187
Depreciation Expense
49 56 92 96 120 132 156
Amortization Expense
284 86 103 116 116 145 205
Non-Cash Adjustments To Reconcile Net Income
41 35 200 199 180 225 386
Changes in Operating Assets and Liabilities, net
-660 -149 414 -470 -640 -427 -234
Net Cash From Investing Activities
-88 -250 -481 -420 -260 -513 -390
Net Cash From Continuing Investing Activities
-88 -250 -481 -420 -260 -513 -390
Purchase of Property, Plant & Equipment
-92 -255 -192 -196 -251 -175 -162
Acquisitions
0.00 0.00 -296 -231 -10 -342 -229
Sale of Property, Plant & Equipment
4.00 5.00 7.00 7.00 1.00 4.00 1.00
Net Cash From Financing Activities
-2,932 -2,022 -977 -433 -569 -368 -561
Net Cash From Continuing Financing Activities
-2,932 -2,022 -977 -433 -569 -368 -561
Repayment of Debt
0.00 0.00 -1,742 -108 -338 -1,235 -1,513
Payment of Dividends
0.00 0.00 -145 -290 -294 -297 -88
Issuance of Debt
0.00 1,512 9,470 0.00 80 1,186 1,055
Other Financing Activities, net
-2,932 -3,534 -8,560 -35 -17 -22 -15
Effect of Exchange Rate Changes
31 - 23 -36 17 -76 150

Quarterly Cash Flow Statements for Organon & Co.

This table details how cash moves in and out of Organon & Co.'s business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-118 129 59 -88 -128 52 73 -98 542 16 323
Net Cash From Operating Activities
76 332 141 390 75 220 264 141 225 107 370
Net Cash From Continuing Operating Activities
76 332 141 390 75 220 264 141 225 106 370
Net Income / (Loss) Continuing Operations
201 195 359 109 87 145 160 -205 146 108 164
Consolidated Net Income / (Loss)
201 195 359 109 87 145 160 -205 146 108 164
Depreciation Expense
32 32 34 34 34 36 40 46 39 34 34
Amortization Expense
33 34 35 43 50 53 52 50 47 46 48
Non-Cash Adjustments To Reconcile Net Income
28 50 76 71 35 25 31 295 -47 18 19
Changes in Operating Assets and Liabilities, net
-218 21 -363 133 -131 -39 -19 -45 40 -100 105
Net Cash From Investing Activities
-96 -46 -75 -296 -172 -38 -115 -65 386 -76 -44
Net Cash From Continuing Investing Activities
-96 -46 -75 -296 -172 -38 -115 -65 386 -75 -44
Purchase of Property, Plant & Equipment
-46 -32 -42 -55 -32 -39 -46 -45 -37 -42 -44
Net Cash From Financing Activities
-74 -134 -78 -82 -75 -223 -76 -187 -38 -12 -5.00
Net Cash From Continuing Financing Activities
-74 -134 -78 -82 -75 -223 -76 -187 -38 -12 -5.00
Payment of Dividends
-70 -79 -74 -74 -71 -10 -3.00 -4.00 -5.00 -6.00 -5.00
Other Net Changes in Cash
- - - - - - - - -31 -3.00 2.00

Annual Balance Sheets for Organon & Co.

This table presents Organon & Co.'s assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
10,109 10,681 10,955 12,058 13,101 12,867
Total Current Assets
3,567 3,760 3,931 4,508 4,348 4,352
Cash & Equivalents
12 737 706 693 675 574
Accounts Receivable
1,038 1,382 1,475 1,744 1,358 1,331
Inventories, net
913 915 1,003 1,315 1,321 1,406
Other Current Assets
930 726 747 756 994 1,033
Other Current Nonoperating Assets
674 - - - 0.00 8.00
Plant, Property, & Equipment, net
984 973 1,018 1,183 1,168 1,303
Total Noncurrent Assets
5,558 5,948 6,006 6,367 7,585 7,212
Goodwill
4,603 4,603 4,603 4,603 4,680 4,153
Intangible Assets
503 651 649 533 1,414 1,130
Noncurrent Deferred & Refundable Income Taxes
- 694 - 1,231 - 1,539
Other Noncurrent Nonoperating Assets
91 - - - 0.00 390
Total Liabilities & Shareholders' Equity
10,109 10,681 10,955 12,058 13,101 12,867
Total Liabilities
4,623 12,189 11,847 12,128 12,629 12,115
Total Current Liabilities
2,673 2,597 2,512 2,918 2,718 2,390
Short-Term Debt
0.00 9.00 8.00 9.00 20 16
Accounts Payable
1,598 1,382 1,132 1,314 1,153 952
Accrued Expenses
659 1,021 1,188 1,389 1,411 1,335
Current Deferred & Payable Income Tax Liabilities
288 185 184 206 134 85
Other Current Nonoperating Liabilities
128 - - - 0.00 2.00
Total Noncurrent Liabilities
1,950 9,592 9,335 9,210 9,911 9,725
Long-Term Debt
0.00 9,125 8,905 8,751 8,860 8,628
Noncurrent Deferred & Payable Income Tax Liabilities
128 4.00 19 47 74 57
Other Noncurrent Operating Liabilities
1,739 463 411 412 977 1,008
Other Noncurrent Nonoperating Liabilities
83 - - - 0.00 32
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
5,486 -1,508 -892 -70 472 752
Total Preferred & Common Equity
5,486 -1,508 -892 -70 472 752
Total Common Equity
5,486 -1,508 -892 -70 472 752
Common Stock
0.00 3.00 3.00 28 111 170
Retained Earnings
0.00 -998 -331 443 1,010 1,109
Accumulated Other Comprehensive Income / (Loss)
-622 -513 -564 -541 -649 -527

Quarterly Balance Sheets for Organon & Co.

This table presents Organon & Co.'s assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
10,979 11,012 11,891 12,154 12,752 13,156 13,500 13,552 12,996 13,178 13,401
Total Current Assets
3,958 4,050 4,196 4,509 4,756 4,371 4,618 4,700 4,932 5,111 5,369
Cash & Equivalents
326 414 575 704 763 547 599 672 1,116 1,132 1,455
Accounts Receivable
1,672 1,648 1,547 1,617 1,685 1,457 1,484 1,484 1,384 1,492 1,480
Inventories, net
1,199 1,186 1,263 1,287 1,383 1,362 1,454 1,488 1,373 1,351 1,355
Other Current Assets
761 802 811 901 925 1,005 1,081 1,056 1,059 1,136 1,079
Other Current Nonoperating Assets
- - - - - - - - 0.00 0.00 0.00
Plant, Property, & Equipment, net
1,110 1,096 1,180 1,162 1,204 1,197 1,266 1,290 1,279 1,281 1,286
Total Noncurrent Assets
5,911 5,866 6,515 6,483 6,792 7,588 7,616 7,562 6,785 6,786 6,746
Goodwill
4,603 4,603 4,603 4,603 4,603 4,680 4,680 4,680 4,153 4,153 4,153
Intangible Assets
592 561 718 684 763 1,417 1,362 1,340 1,099 1,112 1,065
Noncurrent Deferred & Refundable Income Taxes
716 702 1,194 1,196 1,426 1,491 - - 1,533 1,521 1,528
Other Noncurrent Nonoperating Assets
- - - - - - - - 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
10,979 11,012 11,891 12,154 12,752 13,156 13,500 13,552 12,996 13,178 13,401
Total Liabilities
11,534 11,601 11,843 12,010 12,259 12,614 12,767 12,646 12,093 12,172 12,208
Total Current Liabilities
2,387 2,491 2,545 2,755 2,790 2,615 2,796 2,679 2,500 2,616 2,652
Short-Term Debt
8.00 8.00 9.00 9.00 10 20 115 45 16 74 69
Accounts Payable
1,115 1,067 955 1,243 1,092 1,006 1,067 1,074 983 1,051 982
Accrued Expenses
1,101 1,255 1,385 1,302 1,458 1,413 1,420 1,444 1,424 1,407 1,522
Current Deferred & Payable Income Tax Liabilities
163 161 196 201 230 176 194 116 77 84 79
Other Current Nonoperating Liabilities
- - - - - - - - 0.00 0.00 0.00
Total Noncurrent Liabilities
9,147 9,110 9,298 9,255 9,469 9,999 9,971 9,967 9,593 9,556 9,556
Long-Term Debt
8,722 8,646 8,705 8,647 8,739 8,936 8,781 8,783 8,553 8,479 8,485
Noncurrent Deferred & Payable Income Tax Liabilities
32 43 44 60 56 69 69 62 56 51 45
Other Noncurrent Operating Liabilities
393 421 549 548 674 994 1,121 1,122 984 1,026 1,026
Other Noncurrent Nonoperating Liabilities
- - - - - - - - 0.00 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-555 -589 48 144 493 542 733 906 903 1,006 1,193
Total Preferred & Common Equity
-555 -589 48 144 493 542 733 906 903 1,006 1,193
Total Common Equity
-555 -589 48 144 493 542 733 906 903 1,006 1,193
Common Stock
3.00 3.00 52 66 89 133 142 162 189 202 221
Retained Earnings
-25 -16 573 690 975 1,026 1,163 1,318 1,253 1,352 1,511
Accumulated Other Comprehensive Income / (Loss)
-533 -576 -577 -612 -571 -617 -572 -574 -539 -548 -539

Annual Metrics And Ratios for Organon & Co.

This table displays calculated financial ratios and metrics derived from Organon & Co.'s official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - -
Revenue Growth
0.00% -16.01% -3.49% -2.06% 1.44% 2.24% -2.92%
EBITDA Growth
0.00% -28.17% -31.51% -10.65% -18.07% 11.99% -19.58%
EBIT Growth
0.00% -25.54% -35.07% -12.76% -22.07% 10.95% -29.99%
NOPAT Growth
0.00% -32.11% -30.73% -18.92% 48.91% -23.01% -75.35%
Net Income Growth
0.00% -32.88% -37.45% -32.12% 11.56% -15.54% -78.36%
EPS Growth
0.00% -32.86% -37.68% -32.39% 11.14% -16.54% -78.38%
Operating Cash Flow Growth
0.00% -24.37% -5.43% -60.28% -6.88% 17.52% -25.45%
Free Cash Flow Firm Growth
0.00% 0.00% 85.33% 321.77% 43.35% -35.62% -26.48%
Invested Capital Growth
0.00% 0.00% 40.02% 6.18% 9.32% 8.50% -2.52%
Revenue Q/Q Growth
0.00% 0.00% -0.16% -1.88% 1.84% -0.09% -1.35%
EBITDA Q/Q Growth
0.00% 0.00% -7.69% -5.24% 1.75% 4.30% -18.97%
EBIT Q/Q Growth
0.00% 0.00% -9.70% -5.34% 1.42% 3.85% -25.68%
NOPAT Q/Q Growth
0.00% 0.00% -5.25% -2.30% 77.11% -33.27% -57.77%
Net Income Q/Q Growth
0.00% 0.00% -10.94% -9.30% 74.87% -33.59% -62.67%
EPS Q/Q Growth
0.00% 0.00% -11.06% -9.11% 74.24% -33.80% -62.50%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -16.83% 34.48% 19.43% -0.74% -26.24%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.67% 118.71% -42.53% 111.05%
Invested Capital Q/Q Growth
0.00% 0.00% 3.25% 2.54% 4.52% 2.34% -6.67%
Profitability Metrics
- - - - - - -
Gross Margin
70.76% 67.56% 61.94% 62.84% 59.84% 58.02% 53.30%
EBITDA Margin
51.81% 44.31% 31.44% 28.68% 23.17% 25.38% 20.75%
Operating Margin
48.37% 42.67% 28.41% 25.43% 20.07% 21.46% 13.26%
EBIT Margin
47.52% 42.13% 28.35% 25.25% 19.40% 21.05% 14.95%
Profit (Net Income) Margin
41.38% 33.07% 21.43% 14.85% 16.33% 13.49% 3.01%
Tax Burden Percent
87.07% 78.49% 88.36% 81.73% 152.01% 107.06% 44.00%
Interest Burden Percent
100.00% 100.00% 85.56% 71.97% 55.39% 59.87% 45.75%
Effective Tax Rate
10.55% 18.02% 11.64% 18.27% -52.01% -7.06% 56.00%
Return on Invested Capital (ROIC)
0.00% 92.87% 26.80% 18.07% 24.96% 17.64% 4.23%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 136.93% 20.89% 13.66% 14.05% 10.18% 2.03%
Return on Net Nonoperating Assets (RNNOA)
0.00% -14.13% 41.12% -94.48% -237.64% 412.21% 26.32%
Return on Equity (ROE)
0.00% 78.75% 67.92% -76.42% -212.68% 429.85% 30.56%
Cash Return on Invested Capital (CROIC)
0.00% -107.13% -6.55% 12.07% 16.05% 9.49% 6.79%
Operating Return on Assets (OROA)
0.00% 27.22% 17.19% 14.41% 10.56% 10.72% 7.16%
Return on Assets (ROA)
0.00% 21.37% 13.00% 8.48% 8.89% 6.87% 1.44%
Return on Common Equity (ROCE)
0.00% 78.75% 67.92% -76.42% -212.68% 429.85% 30.56%
Return on Equity Simple (ROE_SIMPLE)
0.00% 39.37% -89.59% -102.80% -1,461.43% 183.05% 0.00%
Net Operating Profit after Tax (NOPAT)
3,365 2,285 1,582 1,283 1,911 1,471 363
NOPAT Margin
43.27% 34.98% 25.10% 20.78% 30.51% 22.97% 5.83%
Net Nonoperating Expense Percent (NNEP)
0.00% -44.06% 5.91% 4.41% 10.91% 7.46% 2.21%
Return On Investment Capital (ROIC_SIMPLE)
- - - 16.00% 21.99% 15.73% 3.86%
Cost of Revenue to Revenue
29.24% 32.44% 38.06% 37.16% 40.16% 41.98% 46.70%
SG&A Expenses to Revenue
18.55% 20.76% 26.46% 27.60% 30.23% 27.49% 27.69%
R&D to Revenue
2.83% 3.21% 7.03% 9.36% 8.56% 8.59% 5.98%
Operating Expenses to Revenue
22.39% 24.89% 33.53% 37.42% 39.77% 36.56% 40.04%
Earnings before Interest and Taxes (EBIT)
3,696 2,752 1,787 1,559 1,215 1,348 929
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4,029 2,894 1,982 1,771 1,451 1,625 1,290
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 7.99 2.47
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 1.05 1.00 0.54 0.59 0.30
Price to Earnings (P/E)
0.00 0.00 4.91 6.74 3.33 4.37 9.94
Dividend Yield
0.00% 0.00% 2.14% 6.92% 8.40% 7.64% 4.75%
Earnings Yield
0.00% 0.00% 20.37% 14.84% 30.03% 22.90% 10.06%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 2.18 1.97 1.43 1.38 1.17
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 2.38 2.33 1.83 1.87 1.60
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 7.58 8.12 7.91 7.37 7.70
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 8.41 9.23 9.44 8.89 10.69
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 9.50 11.21 6.01 8.14 27.39
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 6.96 16.77 14.36 12.76 14.19
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 16.78 9.34 15.14 17.07
Leverage & Solvency
- - - - - - -
Debt to Equity
0.00 0.00 -6.06 -9.99 -125.14 18.81 11.49
Long-Term Debt to Equity
0.00 0.00 -6.05 -9.98 -125.01 18.77 11.47
Financial Leverage
0.00 -0.10 1.97 -6.92 -16.92 40.48 13.00
Leverage Ratio
0.00 1.84 5.23 -9.02 -23.92 62.58 21.22
Compound Leverage Factor
0.00 1.84 4.47 -6.49 -13.25 37.47 9.71
Debt to Total Capital
0.00% 0.00% 119.77% 111.12% 100.81% 94.95% 92.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.12% 0.10% 0.10% 0.21% 0.17%
Long-Term Debt to Total Capital
0.00% 0.00% 119.66% 111.02% 100.70% 94.74% 91.83%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 100.00% -19.77% -11.12% -0.81% 5.05% 8.00%
Debt to EBITDA
0.00 0.00 4.61 5.03 6.04 5.46 6.70
Net Debt to EBITDA
0.00 0.00 4.24 4.63 5.56 5.05 6.26
Long-Term Debt to EBITDA
0.00 0.00 4.60 5.03 6.03 5.45 6.69
Debt to NOPAT
0.00 0.00 5.77 6.95 4.58 6.04 23.84
Net Debt to NOPAT
0.00 0.00 5.31 6.40 4.22 5.58 22.26
Long-Term Debt to NOPAT
0.00 0.00 5.77 6.94 4.58 6.02 23.80
Altman Z-Score
0.00 0.00 1.47 1.46 1.23 1.26 1.12
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - -
Current Ratio
0.00 1.33 1.45 1.56 1.54 1.60 1.82
Quick Ratio
0.00 0.39 0.82 0.87 0.84 0.75 0.80
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -2,635 -387 857 1,229 791 582
Operating Cash Flow to CapEx
3,431.82% 913.60% 1,167.57% 453.97% 319.60% 549.12% 434.78%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -1.50 1.96 2.27 1.46 1.15
Operating Cash Flow to Interest Expense
0.00 0.00 8.37 1.96 1.47 1.74 1.39
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 7.66 1.53 1.01 1.42 1.07
Efficiency Ratios
- - - - - - -
Asset Turnover
0.00 0.65 0.61 0.57 0.54 0.51 0.48
Accounts Receivable Turnover
0.00 6.29 5.21 4.32 3.89 4.13 4.62
Inventory Turnover
0.00 2.32 2.62 2.39 2.17 2.04 2.13
Fixed Asset Turnover
0.00 6.64 6.44 6.20 5.69 5.45 5.03
Accounts Payable Turnover
0.00 1.33 1.61 1.83 2.06 2.18 2.76
Days Sales Outstanding (DSO)
0.00 58.00 70.06 84.45 93.80 88.41 78.95
Days Inventory Outstanding (DIO)
0.00 157.27 139.06 152.59 168.20 178.97 171.44
Days Payable Outstanding (DPO)
0.00 275.26 226.70 200.00 177.49 167.50 132.33
Cash Conversion Cycle (CCC)
0.00 -59.99 -17.58 37.04 84.51 99.89 118.05
Capital & Investment Metrics
- - - - - - -
Invested Capital
0.00 4,920 6,889 7,315 7,997 8,677 8,458
Invested Capital Turnover
0.00 2.66 1.07 0.87 0.82 0.77 0.73
Increase / (Decrease) in Invested Capital
0.00 4,920 1,969 426 682 680 -219
Enterprise Value (EV)
0.00 0.00 15,029 14,385 11,474 11,978 9,929
Market Capitalization
0.00 0.00 6,632 6,178 3,407 3,773 1,859
Book Value per Share
$0.00 $21.64 ($5.95) ($3.51) ($0.27) $1.83 $2.89
Tangible Book Value per Share
$0.00 $1.50 ($26.67) ($24.15) ($20.37) ($21.83) ($17.43)
Total Capital
0.00 5,486 7,626 8,021 8,690 9,352 9,396
Total Debt
0.00 0.00 9,134 8,913 8,760 8,880 8,644
Total Long-Term Debt
0.00 0.00 9,125 8,905 8,751 8,860 8,628
Net Debt
0.00 -12 8,397 8,207 8,067 8,205 8,070
Capital Expenditures (CapEx)
88 250 185 189 250 171 161
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 882 435 721 906 975 1,404
Debt-free Net Working Capital (DFNWC)
0.00 894 1,172 1,427 1,599 1,650 1,978
Net Working Capital (NWC)
0.00 894 1,163 1,419 1,590 1,630 1,962
Net Nonoperating Expense (NNE)
147 125 231 366 888 607 176
Net Nonoperating Obligations (NNO)
0.00 -566 8,397 8,207 8,067 8,205 7,706
Total Depreciation and Amortization (D&A)
333 142 195 212 236 277 361
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 13.50% 6.90% 11.68% 14.47% 15.23% 22.59%
Debt-free Net Working Capital to Revenue
0.00% 13.69% 18.59% 23.11% 25.53% 25.77% 31.82%
Net Working Capital to Revenue
0.00% 13.69% 18.45% 22.98% 25.39% 25.46% 31.56%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $5.33 $3.61 $4.01 $3.36 $0.72
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 253.54M 254.08M 255.24M 257.05M 259.50M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $5.31 $3.59 $3.99 $3.33 $0.72
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 254.19M 255.17M 256.27M 259.15M 260.76M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 253.64M 254.38M 255.64M 257.95M 260.32M
Normalized Net Operating Profit after Tax (NOPAT)
3,435 2,334 1,585 1,306 923 984 854
Normalized NOPAT Margin
44.17% 35.73% 25.15% 21.15% 14.74% 15.36% 13.74%
Pre Tax Income Margin
47.52% 42.13% 24.25% 18.17% 10.75% 12.60% 6.84%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
0.00 0.00 6.93 3.57 2.24 2.49 1.84
NOPAT to Interest Expense
0.00 0.00 6.13 2.94 3.53 2.72 0.72
EBIT Less CapEx to Interest Expense
0.00 0.00 6.21 3.14 1.78 2.18 1.52
NOPAT Less CapEx to Interest Expense
0.00 0.00 5.42 2.50 3.06 2.40 0.40
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% 0.00% 10.73% 31.62% 28.74% 34.38% 47.06%
Augmented Payout Ratio
0.00% 0.00% 10.73% 31.62% 28.74% 34.38% 47.06%

Quarterly Metrics And Ratios for Organon & Co.

This table displays calculated financial ratios and metrics derived from Organon & Co.'s official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 260,315,650.00 262,600,862.00 262,609,433.00
DEI Adjusted Shares Outstanding
- - - - - - - - 260,315,650.00 262,600,862.00 262,609,433.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - 0.56 0.41 0.62
Growth Metrics
- - - - - - - - - - -
Revenue Growth
5.46% -0.06% 4.15% -0.38% -6.72% -0.81% 1.26% -5.34% -3.50% -2.26% -1.75%
EBITDA Growth
1.89% -2.92% 46.18% 16.94% -25.69% 3.94% 15.17% -83.14% 32.69% -17.37% -4.32%
EBIT Growth
0.00% -5.43% 55.61% 14.17% -35.42% -1.64% 11.41% -114.94% 44.00% -19.17% -2.70%
NOPAT Growth
11.30% -16.94% 249.54% -81.75% -37.33% -33.36% -59.91% -126.18% -19.74% -7.37% -0.41%
Net Income Growth
13.56% -19.42% 518.97% -80.04% -56.72% -25.64% -55.43% -288.07% 67.82% -25.52% 2.50%
EPS Growth
13.04% -21.05% 500.00% -80.19% -57.69% -25.33% -55.80% -285.71% 66.67% -28.57% -1.64%
Operating Cash Flow Growth
-33.33% 1,129.63% -45.98% -1.76% -1.32% -33.73% 87.23% -63.85% 200.00% -51.36% 40.15%
Free Cash Flow Firm Growth
-355.17% 122.76% 31.17% -167.02% -60.14% -1,297.76% -44.66% 135.57% 234.22% 208.81% 389.32%
Invested Capital Growth
8.94% 3.15% 10.82% 8.50% 9.33% 11.54% 6.88% -2.52% -6.65% -6.68% -8.50%
Revenue Q/Q Growth
1.50% -0.92% -1.56% 0.63% -4.96% 5.35% 0.50% -5.93% -3.12% 6.71% 1.03%
EBITDA Q/Q Growth
47.95% 0.00% -6.94% -10.70% -10.59% 39.88% 3.12% -87.69% 619.30% -9.51% 19.41%
EBIT Q/Q Growth
58.19% -0.27% -9.02% -15.32% -15.96% 51.90% 3.06% -110.51% 930.77% -10.19% 24.06%
NOPAT Q/Q Growth
-74.48% -3.87% 90.98% -58.61% -17.52% 2.22% 14.90% -127.02% 352.87% 17.97% 23.53%
Net Income Q/Q Growth
-63.19% -2.99% 84.10% -69.64% -20.18% 66.67% 10.34% -228.13% 171.22% -26.03% 51.85%
EPS Q/Q Growth
-63.21% -3.85% 84.00% -69.57% -21.43% 69.70% 8.93% -227.87% 170.51% -27.27% 50.00%
Operating Cash Flow Q/Q Growth
-80.86% 336.84% -57.53% 176.60% -80.77% 193.33% 20.00% -46.59% 59.57% -52.44% 245.79%
Free Cash Flow Firm Q/Q Growth
-161.42% 117.30% -494.52% -81.88% -29.00% -29.39% 52.35% 144.72% 386.85% 4.89% 26.70%
Invested Capital Q/Q Growth
2.38% -1.11% 4.73% 2.34% 3.16% 0.88% 0.35% -6.67% -1.21% 0.85% -1.60%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
59.00% 58.43% 58.34% 56.28% 55.58% 54.83% 53.50% 49.17% 53.63% 54.36% 55.21%
EBITDA Margin
26.63% 26.88% 25.41% 22.55% 21.22% 28.17% 28.90% 3.78% 28.08% 23.81% 28.14%
Operating Margin
23.18% 23.09% 21.43% 18.09% 15.40% 20.33% 22.35% -6.04% 16.10% 20.67% 23.19%
EBIT Margin
22.63% 22.78% 21.05% 17.71% 15.66% 22.58% 23.16% -2.59% 22.19% 18.68% 22.94%
Profit (Net Income) Margin
12.39% 12.13% 22.69% 6.85% 5.75% 9.10% 9.99% -13.60% 10.00% 6.93% 10.42%
Tax Burden Percent
85.17% 82.98% 173.43% 84.50% 86.14% 63.32% 65.84% 138.51% 68.54% 59.02% 64.31%
Interest Burden Percent
64.31% 64.21% 62.16% 45.74% 42.62% 63.61% 65.50% 379.49% 65.74% 62.89% 70.64%
Effective Tax Rate
14.83% 17.02% -73.43% 15.50% 13.86% 36.68% 34.16% 0.00% 31.46% 40.98% 35.69%
Return on Invested Capital (ROIC)
15.96% 15.25% 29.53% 11.74% 9.74% 9.44% 10.57% -3.07% 7.86% 8.56% 10.48%
ROIC Less NNEP Spread (ROIC-NNEP)
14.51% 13.87% 26.71% 10.09% 8.37% 8.70% 9.63% -4.84% 7.67% 7.52% 9.56%
Return on Net Nonoperating Assets (RNNOA)
-345.10% -551.91% -4,514.71% 408.36% 234.73% 161.19% 111.15% -62.95% 84.17% 67.95% 69.45%
Return on Equity (ROE)
-329.14% -536.66% -4,485.18% 420.10% 244.48% 170.63% 121.72% -66.02% 92.02% 76.51% 79.93%
Cash Return on Invested Capital (CROIC)
15.90% 20.23% 17.07% 9.49% 7.12% 3.63% 3.14% 6.79% 11.25% 10.93% 12.93%
Operating Return on Assets (OROA)
12.68% 12.50% 11.35% 9.02% 7.87% 11.06% 11.10% -1.24% 10.46% 8.58% 10.38%
Return on Assets (ROA)
6.94% 6.66% 12.24% 3.49% 2.89% 4.45% 4.78% -6.51% 4.71% 3.18% 4.72%
Return on Common Equity (ROCE)
-329.14% -536.66% -4,485.18% 420.10% 244.48% 170.63% 121.72% -66.02% 92.02% 76.51% 79.93%
Return on Equity Simple (ROE_SIMPLE)
2,181.25% 694.44% 263.89% 0.00% 138.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
320 308 588 243 201 205 236 -64 161 190 235
NOPAT Margin
19.74% 19.16% 37.16% 15.29% 13.27% 12.87% 14.71% -4.23% 11.03% 12.20% 14.91%
Net Nonoperating Expense Percent (NNEP)
1.45% 1.38% 2.82% 1.65% 1.37% 0.74% 0.94% 1.78% 0.19% 1.04% 0.93%
Return On Investment Capital (ROIC_SIMPLE)
- - - 2.60% 2.11% 2.13% 2.42% -0.68% 1.70% 1.99% 2.41%
Cost of Revenue to Revenue
41.00% 41.57% 41.66% 43.72% 44.42% 45.17% 46.50% 50.83% 46.37% 45.64% 44.79%
SG&A Expenses to Revenue
26.57% 27.19% 26.68% 29.52% 27.76% 28.42% 25.91% 28.73% 29.04% 27.86% 26.75%
R&D to Revenue
7.83% 8.15% 10.24% 8.17% 6.74% 5.96% 5.24% 6.04% 6.37% 5.84% 5.27%
Operating Expenses to Revenue
35.82% 35.35% 36.92% 38.19% 40.19% 34.50% 31.15% 55.21% 37.53% 33.70% 32.02%
Earnings before Interest and Taxes (EBIT)
367 366 333 282 237 360 371 -39 324 291 361
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
432 432 402 359 321 449 463 57 410 371 443
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
97.38 36.46 9.99 7.99 7.09 3.43 3.06 2.47 1.73 3.53 3.02
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.74 0.83 0.77 0.59 0.61 0.40 0.44 0.30 0.25 0.58 0.59
Price to Earnings (P/E)
4.46 5.25 3.79 4.37 5.12 3.59 5.54 9.94 6.34 17.01 16.89
Dividend Yield
6.12% 5.49% 5.85% 7.64% 7.52% 8.88% 5.62% 4.75% 1.34% 0.59% 0.58%
Earnings Yield
22.40% 19.05% 26.41% 22.90% 19.53% 27.82% 18.04% 10.06% 15.78% 5.88% 5.92%
Enterprise Value to Invested Capital (EV/IC)
1.57 1.63 1.52 1.38 1.37 1.20 1.21 1.17 1.08 1.30 1.29
Enterprise Value to Revenue (EV/Rev)
2.02 2.08 2.01 1.87 1.95 1.72 1.74 1.60 1.46 1.79 1.75
Enterprise Value to EBITDA (EV/EBITDA)
8.87 9.23 8.29 7.37 8.09 7.06 6.87 7.70 6.48 8.36 8.27
Enterprise Value to EBIT (EV/EBIT)
10.68 11.20 9.95 8.89 10.06 8.92 8.75 10.69 8.77 11.45 11.27
Enterprise Value to NOPAT (EV/NOPAT)
6.67 7.10 5.86 8.14 8.92 8.69 12.73 27.39 23.82 31.30 30.40
Enterprise Value to Operating Cash Flow (EV/OCF)
16.84 12.38 13.65 12.76 13.06 13.09 11.52 14.19 10.60 14.89 12.69
Enterprise Value to Free Cash Flow (EV/FCFF)
10.27 8.19 9.38 15.14 20.09 34.83 39.67 17.07 9.26 11.51 9.53
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
181.54 60.11 17.75 18.81 16.52 12.14 9.74 11.49 9.49 8.50 7.17
Long-Term Debt to Equity
181.35 60.05 17.73 18.77 16.49 11.98 9.69 11.47 9.47 8.43 7.11
Financial Leverage
-23.79 -39.80 -169.02 40.48 28.05 18.53 11.54 13.00 10.98 9.04 7.27
Leverage Ratio
-32.88 -56.28 -247.54 62.58 42.45 29.25 18.80 21.22 18.10 15.34 12.84
Compound Leverage Factor
-21.14 -36.14 -153.88 28.63 18.09 18.61 12.32 80.51 11.90 9.65 9.07
Debt to Total Capital
99.45% 98.36% 94.67% 94.95% 94.29% 92.39% 90.69% 92.00% 90.47% 89.48% 87.76%
Short-Term Debt to Total Capital
0.10% 0.10% 0.11% 0.21% 0.21% 1.19% 0.46% 0.17% 0.17% 0.77% 0.71%
Long-Term Debt to Total Capital
99.35% 98.26% 94.56% 94.74% 94.08% 91.19% 90.23% 91.83% 90.30% 88.70% 87.05%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.55% 1.64% 5.33% 5.05% 5.71% 7.61% 9.31% 8.00% 9.53% 10.52% 12.24%
Debt to EBITDA
6.03 6.05 5.62 5.46 5.92 5.81 5.55 6.70 6.16 6.51 6.62
Net Debt to EBITDA
5.64 5.56 5.13 5.05 5.55 5.42 5.12 6.26 5.36 5.65 5.49
Long-Term Debt to EBITDA
6.03 6.04 5.61 5.45 5.90 5.74 5.52 6.69 6.15 6.46 6.56
Debt to NOPAT
4.54 4.65 3.97 6.04 6.52 7.15 10.28 23.84 22.65 24.39 24.31
Net Debt to NOPAT
4.24 4.28 3.62 5.58 6.12 6.67 9.50 22.26 19.70 21.16 20.17
Long-Term Debt to NOPAT
4.53 4.65 3.96 6.02 6.50 7.06 10.23 23.80 22.60 24.17 24.11
Altman Z-Score
1.11 1.14 1.12 1.00 0.99 0.95 1.00 0.87 0.99 1.08 1.12
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.65 1.64 1.70 1.60 1.67 1.65 1.75 1.82 1.97 1.95 2.02
Quick Ratio
0.83 0.84 0.88 0.75 0.77 0.75 0.80 0.80 1.00 1.00 1.11
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-352 61 -240 -437 -563 -729 -347 155 756 793 1,005
Operating Cash Flow to CapEx
165.22% 1,037.50% 343.90% 735.85% 234.38% 564.10% 573.91% 313.33% 608.11% 254.76% 840.91%
Free Cash Flow to Firm to Interest Expense
-2.69 0.46 -1.91 -2.85 -4.14 -5.56 -2.71 1.42 6.81 7.34 9.48
Operating Cash Flow to Interest Expense
0.58 2.53 1.12 2.55 0.55 1.68 2.06 1.29 2.03 0.99 3.49
Operating Cash Flow Less CapEx to Interest Expense
0.23 2.29 0.79 2.20 0.32 1.38 1.70 0.88 1.69 0.60 3.08
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.56 0.55 0.54 0.51 0.50 0.49 0.48 0.48 0.47 0.46 0.45
Accounts Receivable Turnover
4.24 3.86 3.85 4.13 4.19 4.05 3.98 4.62 4.34 4.12 4.12
Inventory Turnover
2.19 2.13 2.09 2.04 2.05 2.00 1.97 2.13 2.13 2.07 2.01
Fixed Asset Turnover
5.68 5.59 5.57 5.45 5.30 5.17 5.05 5.03 4.98 4.81 4.74
Accounts Payable Turnover
2.68 2.24 2.49 2.18 2.75 2.38 2.62 2.76 2.92 2.74 2.78
Days Sales Outstanding (DSO)
86.03 94.59 94.91 88.41 87.10 90.10 91.79 78.95 84.13 88.64 88.69
Days Inventory Outstanding (DIO)
166.38 171.66 174.29 178.97 177.76 182.10 184.95 171.44 171.64 176.58 181.48
Days Payable Outstanding (DPO)
136.16 162.82 146.47 167.50 132.80 153.47 139.53 132.33 124.83 133.33 131.24
Cash Conversion Cycle (CCC)
116.25 103.42 122.73 99.89 132.07 118.74 137.20 118.05 130.95 131.89 138.93
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
8,187 8,096 8,479 8,677 8,951 9,030 9,062 8,458 8,356 8,427 8,292
Invested Capital Turnover
0.81 0.80 0.79 0.77 0.73 0.73 0.72 0.73 0.71 0.70 0.70
Increase / (Decrease) in Invested Capital
672 247 828 680 764 934 583 -219 -595 -603 -770
Enterprise Value (EV)
12,813 13,202 12,911 11,978 12,250 10,813 10,932 9,929 9,012 10,977 10,697
Market Capitalization
4,674 5,250 4,925 3,773 3,841 2,516 2,776 1,859 1,559 3,556 3,598
Book Value per Share
$0.19 $0.56 $1.91 $1.83 $2.10 $2.82 $3.49 $2.89 $3.47 $3.83 $4.54
Tangible Book Value per Share
($20.62) ($20.00) ($18.93) ($21.83) ($21.54) ($20.42) ($19.67) ($17.43) ($16.71) ($16.22) ($15.33)
Total Capital
8,762 8,800 9,242 9,352 9,498 9,629 9,734 9,396 9,472 9,559 9,747
Total Debt
8,714 8,656 8,749 8,880 8,956 8,896 8,828 8,644 8,569 8,553 8,554
Total Long-Term Debt
8,705 8,647 8,739 8,860 8,936 8,781 8,783 8,628 8,553 8,479 8,485
Net Debt
8,139 7,952 7,986 8,205 8,409 8,297 8,156 8,070 7,453 7,421 7,099
Capital Expenditures (CapEx)
46 32 41 53 32 39 46 45 37 42 44
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,085 1,059 1,213 975 1,229 1,338 1,394 1,404 1,332 1,437 1,331
Debt-free Net Working Capital (DFNWC)
1,660 1,763 1,976 1,650 1,776 1,937 2,066 1,978 2,448 2,569 2,786
Net Working Capital (NWC)
1,651 1,754 1,966 1,630 1,756 1,822 2,021 1,962 2,432 2,495 2,717
Net Nonoperating Expense (NNE)
119 113 229 134 114 60 76 141 15 82 71
Net Nonoperating Obligations (NNO)
8,139 7,952 7,986 8,205 8,409 8,297 8,156 7,706 7,453 7,421 7,099
Total Depreciation and Amortization (D&A)
65 66 69 77 84 89 92 96 86 80 82
Debt-free, Cash-free Net Working Capital to Revenue
17.09% 16.69% 18.93% 15.23% 19.53% 21.30% 22.12% 22.59% 21.61% 23.45% 21.82%
Debt-free Net Working Capital to Revenue
26.15% 27.78% 30.83% 25.77% 28.22% 30.84% 32.79% 31.82% 39.72% 41.93% 45.68%
Net Working Capital to Revenue
26.01% 27.64% 30.68% 25.46% 27.90% 29.01% 32.07% 31.56% 39.46% 40.72% 44.55%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.78 $0.76 $1.39 $0.43 $0.34 $0.56 $0.61 ($0.79) $0.56 $0.41 $0.62
Adjusted Weighted Average Basic Shares Outstanding
255.70M 257.29M 257.50M 257.05M 257.86M 259.94M 259.98M 259.50M 260.37M 262.61M 262.62M
Adjusted Diluted Earnings per Share
$0.78 $0.75 $1.38 $0.42 $0.33 $0.56 $0.61 ($0.78) $0.55 $0.40 $0.60
Adjusted Weighted Average Diluted Shares Outstanding
258.36M 258.60M 259.76M 259.15M 261.00M 260.16M 260.65M 260.76M 262.90M 270.45M 272.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
257.17M 257.47M 257.54M 257.95M 259.96M 259.97M 259.98M 260.32M 262.60M 262.61M 262.62M
Normalized Net Operating Profit after Tax (NOPAT)
340 308 237 250 275 206 236 -59 182 190 235
Normalized NOPAT Margin
20.95% 19.16% 15.00% 15.71% 18.16% 12.95% 14.71% -3.90% 12.49% 12.20% 14.91%
Pre Tax Income Margin
14.55% 14.62% 13.08% 8.10% 6.68% 14.37% 15.17% -9.82% 14.59% 11.75% 16.20%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
2.80 2.79 2.64 1.84 1.74 2.75 2.90 -0.36 2.92 2.69 3.41
NOPAT to Interest Expense
2.44 2.35 4.67 1.59 1.48 1.57 1.84 -0.58 1.45 1.76 2.21
EBIT Less CapEx to Interest Expense
2.45 2.55 2.32 1.50 1.51 2.45 2.54 -0.77 2.59 2.31 2.99
NOPAT Less CapEx to Interest Expense
2.09 2.11 4.34 1.24 1.24 1.27 1.48 -1.00 1.12 1.37 1.80
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
27.79% 29.60% 22.75% 34.38% 39.73% 32.71% 31.54% 47.06% 8.94% 8.61% 9.39%
Augmented Payout Ratio
27.79% 29.60% 22.75% 34.38% 39.73% 32.71% 31.54% 47.06% 8.94% 8.61% 9.39%

Financials Breakdown Chart

Key Financial Trends

Organon’s latest results show a mixed picture. Revenue increased sequentially from $1.46 billion in Q1 2026 to $1.56 billion in Q2, but remained below the $1.59 billion reported in Q2 2025 and the $1.61 billion recorded in Q2 2024. Gross profit rose to $847 million from $783 million in Q1, lifting the gross margin to approximately 54.4%. Operating income also improved sequentially to $322 million, although net income declined to $108 million from $146 million because of higher net other expense and taxes.

Organon continues to generate positive operating cash flow, but cash conversion weakened in the latest quarter. Operating cash flow fell to $107 million in Q2 2026 from $225 million in Q1 and $220 million a year earlier, primarily because changes in operating assets and liabilities consumed $100 million. After $42 million of capital expenditures, estimated free cash flow was approximately $65 million. The company’s cash balance remained strong at $1.13 billion, supported in part by a $433 million divestiture payment received in Q1.

The balance sheet has improved in liquidity terms, but leverage remains the primary financial risk. Total debt declined to approximately $8.55 billion from $8.90 billion in Q2 2025, while cash increased substantially. However, debt remains more than eight times reported common equity, and interest expense was still $108 million in the quarter. Investors should also note that the supplied historical statements include restatements and calculated cash-flow figures, so comparisons should be interpreted as directional rather than perfectly like-for-like.

  • Liquidity has improved: cash and equivalents increased to $1.13 billion in Q2 2026 from $599 million in Q2 2025 and $547 million in Q1 2025.
  • Debt has trended lower: total short- and long-term debt fell to about $8.55 billion from $8.90 billion a year earlier and approximately $9.04 billion in Q3 2024.
  • Operating profitability remains solid: Q2 operating income was $322 million, or roughly 20.7% of revenue, compared with $235 million in Q1 2025 and a $91 million operating loss in Q4 2025.
  • Restructuring pressure eased: Organon reported no restructuring charge in Q2 2026, compared with $31 million in Q1 2026 and $7 million in Q4 2025.
  • Current assets exceed current liabilities: the Q2 current ratio was approximately 1.95, an improvement from about 1.65 in Q2 2025, although a large portion of current assets consists of receivables and inventory rather than cash.
  • Revenue remains below prior-year levels: Q2 2026 revenue declined approximately 2.3% year over year, continuing a pattern of quarterly revenue generally ranging between roughly $1.5 billion and $1.6 billion rather than showing sustained growth.
  • Net income weakened: Q2 earnings fell to $108 million from $145 million a year earlier, while diluted EPS declined to $0.40 from $0.56.
  • Cash-flow conversion deteriorated: operating cash flow dropped to $107 million from $220 million in Q2 2025, and working-capital changes reduced cash flow by $100 million.
  • Leverage remains elevated: approximately $8.55 billion of debt compares with only $1.01 billion of common equity, leaving Organon highly sensitive to refinancing conditions and interest costs.
  • Dividend support appears reduced: Q1 2026 dividends per share were reported at $0.02, compared with $0.28 per share in the comparable 2025 and 2024 quarters, suggesting a substantially lower cash return to shareholders.
11/16/26 11:47 AM ETAI Generated. May Contain Errors.

Organon & Co. Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Organon & Co.'s fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Organon & Co.'s net income appears to be on a downward trend, with a most recent value of $187 million in 2025, falling from $3.22 billion in 2019. The previous period was $864 million in 2024. Check out Organon & Co.'s forecast to explore projected trends and price targets.

Organon & Co.'s total operating income in 2025 was $824 million, based on the following breakdown:
  • Total Gross Profit: $3.31 billion
  • Total Operating Expenses: $2.49 billion

Over the last 6 years, Organon & Co.'s total revenue changed from $7.78 billion in 2019 to $6.22 billion in 2025, a change of -20.1%.

In the past 13 quarters, Organon & Co.'s cash and equivalents has ranged from $326 million in Q2 2023 to $1.46 billion in Q3 2026, and is currently $1.46 billion as of their latest financial filing in Q3 2026.

Organon & Co. had total debt of $8.64 billion at the end of 2025, a 2.7% decrease from 2024, and none in 2019.

Over the last 6 years, Organon & Co.'s book value per share changed from 0.00 in 2019 to 2.89 in 2025, a change of 289.3%.



Financial statements for NYSE:OGN last updated on 10/30/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners